Accumetrics, Inc. a privately-held medical device company and maker of the VerifyNow family of tests that measure patient response to antiplatelet drugs, announced today that it has raised $28.8 million in its Series D financing. The syndicate was led by Arnerich Massena & Associates, Inc. and BBT Fund, L.P. Also participating in the round were previous investors: Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.
ST. LOUIS, MO and CLEVELAND, OH – RiverVest Venture Partners, a life science venture capital firm headquartered in St. Louis, MO, announced today that it will be opening an office at the BioEnterprise facility in Cleveland, OH. The office will be managed by Karen Spilizewski, who is joining RiverVest on a part-time basis as a vice president on January 1, 2008.
Excaliard closes $15.5 million Series A financing from Alta Partners, ProQuest Investments and RiverVest Venture Partners
CARLSBAD, CA and ENCINITAS, CA – Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Excaliard Pharmaceuticals, Inc. announced today a new collaboration to discover and develop antisense drugs for the local treatment of fibrotic diseases, including scarring.
SEATTLE, WA and SUNNYVALE, CA – Calypso Medical and IMPAC Medical Systems, an Elekta company, have identified product collaboration projects which will further enable integration of oncology management systems with the Calypso® 4D Localization System™.
Lilly to Acquire Phase III Molecule Teplizumab for the Treatment of Type 1 Diabetes Companies to Collaborate on the Development of Autoimmune Disease Treatments
INDIANAPOLIS, IN and ROCKVILLE, MD – Eli Lilly and Company (NYSE:LLY) and MacroGenics, Inc. today announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, today announced that Gordon Foulkes, Ph.D., has joined the firm as a Venture Partner. Dr. Foulkes brings to RiverVest extensive operational experience in biopharmaceutical research and development.
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, has named Dennis Wahr, M.D., to the position of managing director. Wahr, a specialist in cardiac medicine, brings to the firm more than 25 years of experience in clinical practice and medical device entrepreneurship.
ST. LOUIS, MO – RiverVest Venture Partners, a national venture capital firm focusing on seed and early-stage life sciences investments, has named Scott R. Naisbitt, M.D., Ph.D. an associate and Floyd E. Bloom, M.D., a scientific advisor.
ST. LOUIS, MO – RiverVest Venture Partners announced today that the fundraising for RiverVest Venture Fund I, L.P. is complete, closing with $89 million of capital under management. The firm’s founders and managing directors are Andrew B. Craig III, Thomas C. Melzer, Jay W. Schmelter and Mark J. Mendel, Ph.D.